# 1 Original Article

- 2
- 3 Lack of latent tuberculosis screening in HIV patients and delay in Anti-
- 4 Retroviral Therapy initiation in HIV-TB co-infection: A 11-year study in an
- 5 intermediate TB-burden country
- 6 Vannesa Yue May Teng<sup>1</sup>, Yan Ting Chua<sup>1</sup>, Eunice En Ni Lai<sup>1</sup>, Shilpa Mukherjee<sup>1</sup>,
- 7 Jessica Michaels<sup>1</sup>, Chen Seong Wong<sup>2,3</sup>, Yee Sin Leo<sup>2,3,4</sup>, Barnaby Young<sup>2,3,4</sup>,
- 8 Sophia Archuleta<sup>1,5</sup>, Catherine W.M. Ong<sup>1,5,6</sup>
- 9

### 10 Affiliations

- <sup>1</sup>Department of Medicine, National University Hospital, National University Health
- 12 System Singapore;
- 13 <sup>2</sup>National Centre for Infectious Disease, Singapore
- <sup>3</sup> Department of Infectious Disease, Tan Tock Seng Hospital, Singapore
- <sup>4</sup>Lee Kong Chian school of Medicine, Nanyang Technological University Singapore,
- 16 Singapore
- <sup>5</sup>Department of Medicine, Yong Loo Lin School of Medicine, National University of
- 18 Singapore
- <sup>19</sup> <sup>6</sup>Institute for Health Innovation & Technology, National University of Singapore
- 20
- 21 Corresponding Author:
- 22 Vannesa Teng Yue May
- 23 10<sup>th</sup> floor Tower Block, 1E Kent Ridge Road, Singapore 119228
- 24 vannesa\_teng@nuhs.edu.sg
- 25 Telephone number: +65 98164277
- 26
- 27 Co-Corresponding Author
- 28 Catherine W.M. Ong
- 29 10<sup>th</sup> floor Tower Block, 1E Kent Ridge Road, Singapore 119228
- 30 Email: catherine\_wm\_ong@nuhs.edu.sg
- 31 Telephone number: +65 6772 7854
- 32
- 33 Word Count: 2505
- 34 Page count: 19
- 35 Figures: 3
- 36 References: 28
- 37

#### 38 ABSTRACT (250 words)

#### 39 Objectives

- 40 Tuberculosis (TB) is a common infection in HIV patients. Our study aims to determine
- 41 the prevalence and characteristics of HIV-TB co-infected patients in Singapore, a
- 42 high-income, intermediate TB-burden country.

#### 43 Methods

- 44 Retrospective data of 11-years was obtained from the National University Hospital
- 45 (NUH), a quaternary care hospital and the National Centre for Infectious Diseases,
- 46 the national HIV centre.

#### 47 **Results**

48 From December 2005 to December 2016, 48 out of 819 HIV patients and 272 out of 49 3,196 HIV patients who were managed in NUH and TTSH respectively, were 50 diagnosed with TB. 89.1% (n=285) were males and 2 (0.6%) were screened for 51 latent TB on HIV diagnosis. The median age at TB diagnosis was 47.3 years old 52 (Interquartile range, IQR 41-57). Mean CD4 count at TB diagnosis was 125.0 ± 153.9 53 cells/mm<sup>3</sup>. 124 (38.6%) patients had CD4 < 50 cells/mm<sup>3</sup>. 41.3% (n=132) of patients 54 had HIV diagnosed at least 6 weeks before TB diagnosis, indicating an opportunity to 55 initiate latent TB preventive therapy. 55.0% (n=176) had HIV and TB concomitantly 56 diagnosed within 6 weeks whilst 2.25% (n=7) had TB diagnosed before HIV. Of those HIV-TB co-infected patients with CD4  $\leq$  50 cells/mm<sup>3</sup>, 18 (14.2%) had anti-retroviral 57 58 therapy (ART) started <2 weeks. TB-related mortality was 5.3% (n=17) and 3.75% 59 (n=12) were lost to follow-up.

### 60 **Conclusion**

There is a lack of latent TB screening in HIV patients and a delay in initiation of ART in HIV-TB patients with low CD4 counts in our study. Clinical practices can be further improved for the benefit of outcomes in HIV-TB patients.

64

#### 66 Introduction

67 In 2019, there was an estimated 10 million new cases of tuberculosis (TB) diagnosed 68 globally, of whom 815,000 of them were among people living with HIV (1). People 69 living with HIV are more susceptible to active TB infection either from reactivation of 70 latent infection or primary infection. HIV infection is estimated to increase the risks of 71 developing TB by 16-27 times compared to those without HIV infection (2). TB 72 remains the leading cause of death in the HIV population worldwide even though TB 73 is both preventable and treatable. Globally, approximately 208,000 people with HIV 74 died from TB in 2019, which may be worsened by the COVID-19 pandemic (1). 75 Reasons for poorer clinical outcomes for HIV-TB co-infected patients include delays 76 in initiation of anti-retroviral therapy (ART) and/or TB treatment, late detection of HIV-77 associated TB and multi-drug resistance TB (1).

78

79 World Health Organization (WHO) promotes preventive action through early 80 systematic screening and treatment for active and latent TB at the time of HIV 81 diagnosis (1). Treatment of latent TB infection (LTBI) is critical to reduce the risk of 82 progression to active TB with an efficacy ranging 60-90% (3). The guidelines 83 currently recommend testing LTBI using either Interferon Gamma Release Assay 84 (IGRA) or Tuberculin skin test (TST) in high-income and upper middle-income 85 countries with estimated TB incidence less than 100 per 100 000 as they are most 86 likely to benefit due to resource availability and TB epidemiology (3). Despite the end 87 TB strategy by WHO that aims to reduce the incidence rate of TB by 90% by 2035 88 (4), many countries are still not adhering to current guidelines. According to WHO, 89 the percentage of newly diagnosed HIV patients who received preventive LTBI 90 treatment in 2017 in Singapore, Indonesia, India, Philipines, Vietnam, Myanmar, 91 Cambodia was <1%, 16%, 10%, 57%, 31%, 17% and 21% respectively (5).

92

93 Singapore is a high-income economy country with an intermediate TB burden (6), 94 and a healthcare system that is consistently ranked as accessible, equitable and 95 cost-effective by international surveys (7)(8). In Singapore, HIV is managed mainly 96 by the National Centre for Infectious Disease (NCID) and is the national HIV referral 97 center. The HIV programme at the National University Hospital (NUH), a quaternary 98 care centre, was established in 2010. In 2018, out of the 1,421 TB cases who had a 99 HIV test performed, 28 cases (2.0%) were found to have HIV-TB co-infection (9). 100 This study was performed to determine the number of active TB cases in HIV 101 patients, and determine the clinical characteristics of this cohort of patients.

102

# 103 Methods

### 104 Study population

105 Clinical data were retrospectively obtained from Communicable Disease Centre at 106 TTSH (Tan Tock Seng Hospital), predecessor of the NCID (2005 - 2016) and NUH 107 (2010 - 2016). We included all HIV-positive patients, confirmed by Western blot, of at 108 least age 18, who were treated for TB in both hospitals between December 2005 and 109 December 2016. Data collected were patient demographics including gender, age, 110 comorbidities, HIV diagnosis (date of diagnosis, date of initiation of ART, CD4 count 111 at HIV and TB diagnosis, HIV viral load at HIV and TB diagnosis, screening for LTBI 112 at HIV diagnosis), TB characteristics (date of diagnosis, symptoms and duration of 113 presentation, site of infection, method of diagnosis, presence of cavitation, chest 114 radiograph (CXR) findings, physical examination findings), treatment of TB (TB 115 regime and administration, development of IRIS) and clinical outcome (mortality, lost 116 to follow up, TB recurrence, cause of death).

117

#### 118 Definitions

TB was microbiologically diagnosed by positive *Mycobacterium tuberculosis* cultures
or nucleic acid tests. Patients were considered to have clinical TB if they were on TB

121 treatment despite having negative cultures or nucleic acid test. Acid Fast Bacilli 122 (AFB) smear was graded from 0-4, HIV diagnosis was confirmed by Western blotting. 123 CXR were scored 0-10 based on the number of segments involved as previously 124 described by Lawson et al (10). For patients who received treatment in NUH, CXR 125 was scored independently by 3 clinical researchers (Teng V.Y.M, Chua Y.T, Ong 126 C.W.M), and a final score was obtained by the average of 3 scores. For patients 127 managed in TTSH, CXR was scored by a senior clinical researcher (Young, B). LTBI 128 was diagnosed using an interferon gamma release assay (IGRA) (Quantiferon-TB 129 Gold plus; Qiagen) or T-spot TB test (Oxford Immunotec) and/or tuberculin skin test 130 using purified protein derivative (PPD) solution with a cut-off of 10mm as per local 131 practice (9). Multidrug resistant TB was defined as *M.tuberculosis* resistant to both 132 isoniazid and rifampicin. Patients were considered lost to follow-up if they did not turn 133 up for follow up visits after starting treatment or if they have left the country without 134 completion of treatment.

135

### 136 Data Analysis

SPSS software (IBM SPSS, Version 24, USA) and Graphpad Prism (Version 7.0)
was used to perform descriptive statistical analyses. Correlation analysis was
performed using Spearman's coefficients and a p<0.05 was considered statistically</li>
significant.

141

142 Ethics

143 Ethics approval was granted by NHG Domain Specific Review Board (reference144 number 2015/00945).

145

#### 146 **Results**

147 During the 11-year study period, 4,015 HIV patients received medical treatment at 148 TTSH and NUH hospital. 48 out of 819 HIV patients and 272 out of 3,196 HIV

patients were diagnosed with TB, in NUH and TTSH respectively. Out of 320 eligible
patients, the majority were male, with a median age of 47.3 years (IQR 41-57) at TB
diagnosis. 93.8% of this cohort of patients were microbiologically-proven TB.
Smokers comprised 45% of the cohort and a small proportion had diabetes-mellitus
(12.5%) (Table 1).

154

155 The mean CD4 count at TB diagnosis was  $125 \pm 153.9$  cells/mm<sup>3</sup> (mean  $\pm$  S.D.) with 156 76% of patients having a CD4 count  $\leq$ 200 cells/mm<sup>3</sup> at the point of TB diagnosis, 157 indicating profound immunosuppression. Only 2 (0.6%) patients were screened for 158 LTBI upon HIV diagnosis, with equal proportion of unscreened patients above and 159 below CD4 count of 200 cells/mm<sup>3</sup> (Table 1). Both patients were negative for LTBI by 160 IGRA or TST. Irrespective of CD4 counts, 13%, 23% and 39% of patients had ART 161 started <2 weeks, 2-8 weeks, >2 months of TB diagnosis respectively. Of those with 162  $CD4 \le 50$  cells/mm<sup>3</sup>, only 18 (14.2%) had ART started within 2 weeks.

163

164 The most common clinical presentation for TB were fever (75.9%), cough (62%) and 165 weight loss (53.4%). 143 (44.7%) patients had only pulmonary involvement; 39 166 (12.2%) patients had extrapulmonary TB only and 135 (42.2%) patients had both 167 pulmonary and extrapulmonary TB. In total, 278 (86.9%) eligible patients had 168 pulmonary TB out of 320 patients. The lung was the most common site of TB 169 involvement independent of CD4 count. The most common site of extrapulmonary TB 170 was lymph node involvement for both cohorts above and below CD4 of 200 171 cells/mm<sup>3</sup>. In patients with CD4  $\leq$  200 cells/mm<sup>3</sup>, 87% (n=213) had pulmonary TB 172 whilst 59% (n=144) had extra-pulmonary TB (Figure 1A). However, in those with CD4 173 > 200 cells/mm<sup>3</sup>, majority comprising 84% (n=53) had lung involvement whilst 39.6% 174 (n=25) had extra-pulmonary TB involvement (Figure 1B).

175

176 Of those with pulmonary TB, the median CXR score was 4. We found that a total of 177 84 (30.2%) patients had clear CXR despite the presence of pulmonary TB, most of 178 whom were patients with lower CD4 counts. For patients with CD4  $\leq$  200 cells/mm<sup>3</sup> 179 with lung involvement, CXR can be normal which was seen in 37.9% (Figure 2A), 180 and the same is observed in the relative immunocompetent group (Figure 2B). Most 181 of patients in the CD4  $\leq$  200 cells/mm<sup>3</sup> had positive AFB smear results (Figure 2C) 182 with 10% (n=21) of patients with diffuse lung involvement, having a CXR score of 10 (Figure 2A). However, in patients with CD4 > 200 cells/mm<sup>3</sup> with lung involvement. 183 184 only 17% (n=9) patients had clear CXR with a range of AFB smears (Figure 2D), 185 whereas only 3.7% (n=2) patients had diffuse lung involvement (Figure 2B). In both 186 groups, a wide range of AFB smear score from 0 to 4 can be present in patients with 187 a normal CXR (Figure 2E and 2F), indicating that immunocompromised patients can 188 remain highly infectious despite having a normal CXR. Similarly, it was possible to 189 have an AFB smear score of 0 with diffuse TB lung involvement. Interestingly, the 190 AFB smear was positively associated with the degree of CXR score in patients with 191 CD4 > 200 cells/mm<sup>3</sup> (r = 0.33, p<0.05) but this association was not found in patients 192 whose CD4  $\leq$  200 cells/mm<sup>3</sup> (Figure 2E and 2F).

193

194 41.3% (n=132) of patients had HIV diagnosed at least 6 weeks prior to TB diagnosis 195 with a median time-frame of 46 months (IQR 12-91 months) (Figure 3). The mean 196 duration of active TB treatment was  $8.2 \pm 3.5$  months. The majority of patients (83%) 197 were on directly observed treatment (DOT). A small proportion of patients had TB 198 recurrence (3.8%) and development of immune reconstitution inflammatory 199 syndrome (IRIS) (15.6%). Lost to follow-up rate (3.75%) was low, including those 200 who left the country or defaulted follow-up. All cause-mortality was 10% (n=32), out 201 of whom 53% consist of TB-related mortality (n=17) (Table 1).

202

#### 203 Discussion

204 In our study, there was a significant proportion of patients (41%) who had HIV 205 diagnosed at least 6 weeks before TB diagnosis. As culture is the gold standard for 206 diagnosis of active TB and culture result takes 2 to 6 weeks to process, our study 207 team considered 6 weeks to be a reasonable time frame to exclude concurrent HIV-208 TB on presentation (11). Our cohort mainly consisted of clinically advanced HIV 209 disease as 76% had CD4  $\leq$  200 cells/mm<sup>3</sup> at TB diagnosis. However, only 0.6% 210 (n=2) of patients in this study had LTBI screened upon HIV diagnosis, which is a 211 considerably low given WHO recommendations. In developed countries with low TB 212 and HIV burden, the compliance of HIV services in implementing LTBI screening was 213 often inadequate; the LTBI screening rates among HIV patients in United Kingdom, 214 United States and New Zealand was 35%, 32% and 55% respectively (12)(13)(14). 215 The local medical community can further improve on this aspect to prevent active TB 216 in the HIV population.

217

218 Our study found higher rates of TB-HIV co-infection in males. This is in keeping with 219 a systematic review done in the European Union which reported that the majority of 220 HIV-TB co-infected cases were male and young adults, aged between 25-45 years 221 (15). We also found that the prevalence of diabetes mellitus (DM) in our cohort was 222 12% which was similar to a study conducted by Bizune et al in the United States, 223 which reported a prevalence of 9% (16). The high proportion can be explained by 224 diabetes predisposing to TB and ART increasing the risk of metabolic syndrome and 225 thus predisposing to DM (17), and also underscores the increase in DM prevalence 226 in developed countries.

227

Other significant findings in our study included lower than expected proportion (23%)
of patients who were already on ART when diagnosed with TB. This is in contrast
with studies in India and Africa which found that 58% and 40% of HIV-infected patient

were already receiving ART respectively (18)(19). This difference can be explained
by a significant proportion (55%) of our cohort with TB and HIV diagnosed
concomitantly within 6 weeks, hence many of them were not expected to be on ART
when diagnosed with TB.

235

236 Existing studies have reported a variety of chest radiographic appearances of active 237 TB in HIV-positive patients, depending on their level of immunity. In 238 immunocompromised patients, clinical manifestations are atypical as AFB smear can 239 often be positive with normal CXR, or infiltrates are more often present in the lower 240 than the upper lobes (20). 33.5% of our cohort with pulmonary TB had normal CXR 241 which is slightly higher than that reported in other studies which range from 6-21% 242 (21) and may be due to our cohort being more immunocompromised with a mean 243 CD4 count of 125 cells/mm<sup>3</sup>. Therefore, clinicians should exercise caution when 244 using CXR to screen for active TB disease in HIV patients. A high index of suspicion 245 especially in patients presenting with prolonged cough, is required for timely 246 diagnosis of TB in HIV positive patients.

247

248 We found 90% of our HIV-TB cohort to be AFB smear positive with 89% in the group 249 with CD4  $\leq$  200 cells/mm<sup>3</sup> and 94% in the CD4 > 200 cells/mm<sup>3</sup>. This is in contrast to 250 previous studies which reported lower prevalence rates (50-70%) with positive AFB 251 sputum smears in HIV patients (21). This difference may be contributed by higher 252 sensitivity used in our laboratory and other studies not reporting trace results from 253 smear tests, leading to lower rates of smear negative results. The mycobacterial 254 burden was also significantly associated with the degree of CXR involvement only in 255 those with CD4 > 200 cells/mm<sup>3</sup>.

256

257 WHO recommends initiation of ART for HIV-TB coinfected patients within the first 2 258 months of starting TB treatment and within 2 weeks in those severely

259 immunocompromised patients with CD4 counts <50 cells/mm<sup>3</sup>. Prompt initiation of 260 ART to HIV-TB co-infected patients reduces mortality especially in advanced HIV 261 disease (22). Our study showed that only 14% of patients with CD4  $\leq$  50 cells/mm<sup>3</sup> 262 had ARV initiated within 2 weeks. In addition, there was a significant proportion 263 (51.7%) of patients who initiated ART more than 2 months of TB diagnosis, out of 264 which 89% were from patients managed prior to 2011. Majority of delay in ART 265 initiation were prior to the revised WHO ART initiation guidelines in 2010 (23). A 266 study by Escada et al in Brazil found that only 5.4% of patients were initiated on ART 267 within 2 weeks of starting TB treatment, however their cohort had a higher median 268 CD4 count of 91 cells/mm<sup>3</sup> (24).

269

270 DOT is recommended by WHO to promote TB treatment adherence as suboptimal 271 adherence has been associated with unfavourable clinical outcomes (25). Our cohort 272 was able to achieve 83% on DOT, with the remaining using self-administered 273 treatment (SAT). There was a wide variability in the success of implementing DOT in 274 other countries, ranging from 24% in South Africa (26) to 91% in Philippines in HIV-275 TB co-infected patients (27). The main challenges faced worldwide included poor 276 public health infrastructure, poor social support, inadequate funding and lack of 277 awareness about the strategy among practitioners especially in low income, 278 developing countries (27). In our study, TB-related mortality rate was 5.3%. This is 279 much lower than the global rate in 2008 in which TB accounted for about 26% of HIV-280 related deaths (28). Overall, there is ample room for improvement to comply with 281 international guidelines to reduce mortality in our HIV population.

282

The main strength of this study is the detailed clinical data collected for analysis over a 11-year period of cohort of 320 patients. Study limitations include missing data given that this was a retrospective study. In addition, although one of our centres is a

286 referral centre for HIV in Singapore, our data may not be representative of the

287 national HIV-TB situation of the country.

# 289 Conclusion

Early diagnosis of LTBI enables prompt effective treatment to prevent TB-associated deaths. Further improvements are needed to offer routine LTBI screening and treatment in all HIV patients, as recommended by the WHO. In our high-income intermediate TB burden country, there remains a good window of opportunity to reduce the prevalence of HIV-TB co-infection, together with prompt initiation of ART to improve treatment outcomes in this population.

# 314 Acknowledgements

- 315 Catherine W. M. Ong is funded by Singapore National Medical Research Council
- 316 (NMRC/TA/0042/2015, CSAINV17nov014); National University Health System
- 317 Singapore (NUHS/RO/2017/092/SU/01, CFGFY18P11,
- 318 NUHSRO/2020/042/RO5+5/ad-hoc/1), iHealthtech in NUS and recipient of the Young
- 319 Investigator Award, Institut Merieux, Lyon, France.

320

# 321 Author contributions

- 322 Ong C.W.M, Archuleta S. conceived the study. Teng V.Y.M., Chua Y.T., Lai E.E.N.,
- 323 Mukherjee S., Michaels J. and Young B. obtained the data. Teng V.Y.M., Chua Y.T.,
- Lai E.E.N. analysed the data. Teng V.W.M, and Ong C.W.M co-wrote the first draft.
- 325 All authors edited and approved the final version of the manuscript.

- 327
- 328
- 329
- 330
- 331
- 332
- .
- 333
- 334
- 335
- 336 337
- 338
- 339
- 340
- - -
- 341

### 342 References

- 343 1. World Health Organization. Global Tuberculosis Report 2020 [Internet]. WHO. 344 World Health Organization; [cited 2021 Jan 17]. Available from: 345 https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-346 eng.pdf 347 2. WHO | Tuberculosis and HIV [Internet]. WHO. World Health Organization; [cited 348 2020 Jul 25]. Available from: http://www.who.int/hiv/topics/tb/about\_tb/en/ 349 3. WHO | WHO guidelines on the management of latent tuberculosis infection 350 launched today [Internet]. WHO. World Health Organization; [cited 2020 Nov 351 29]. Available from: https://www.who.int/tb/features archive/LTBI/en/ 352 4. WHO | The End TB Strategy [Internet]. WHO. World Health Organization; [cited 353 2020 Nov 29]. Available from: http://www.who.int/tb/strategy/end-tb/en/ 354 Paton NI, Borand L, Benedicto J, Kyi MM, Mahmud AM, Norazmi MN, et al. 5. 355 Diagnosis and management of latent tuberculosis infection in Asia: Review of 356 current status and challenges. International Journal of Infectious Diseases. 357 2019 Oct 1;87:21-9. 358 6. Tam G, Lai SW. Is Singapore on track to eliminate tuberculosis by 2030? A policy 359 case study. SAGE Open Med [Internet]. 2019 May 19 [cited 2020 Jul 25];7. 360 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537069/ 361 Bloomberg's Global Health Index For 2020 | Worldhealth.net Anti-Aging News 7. 362 [Internet]. [cited 2020 Nov 29]. Available from: 363 https://worldhealth.net/news/bloombergs-global-health-index-2020/ 364 8. Tandon A, Murray CJ, Lauer JA, Evans DB. Measuring Overall Health System 365 Performance for 191 Countries. :23. 366 Communicable Diseases Surveillance Singapore 2018. [Internet]. Communicable 367 Diseases Division, Ministry of Health, Singapore; [cited 2020 Nov 29]. Available 368 from: https://www.moh.gov.sg/docs/librariesprovider5/diseases-369 updates/communicable-diseases-surveillance-in-singapore-370 2018210c9a3beaa94db49299c2da53322dce.pdf 371 10. Lawson L, Yassin MA, Thacher TD, Olatunji OO, Lawson JO, Akingbogun TI, et 372 al. Clinical presentation of adults with pulmonary tuberculosis with and without 373 HIV infection in Nigeria. Scandinavian Journal of Infectious Diseases. 2008 374 Jan;40(1):30–5. 375 11. Kwan CK, Ernst JD. HIV and Tuberculosis: a Deadly Human Syndemic. Clinical 376 Microbiology Reviews. 2011 Apr 1;24(2):351–76. 377 12. Latent tuberculosis infection screening and treatment in HIV: insights from 378 evaluation of UK practice | Thorax [Internet]. [cited 2020 Dec 1]. Available from: 379 https://thorax.bmj.com/content/72/2/180 380 13. Adams JW, Howe CJ, Andrews AC, Allen SL, Vinnard C. Tuberculosis screening 381 among HIV-infected patients: tuberculin skin test vs. interferon-gamma release
- 382 assay. AIDS Care. 2017 Dec;29(12):1504–9.

383	<ol> <li>Anwara O, Patrick M, Edeogu C, Kelechi O, Moses A, Oka G. The prevalence of</li></ol>
384	diabetes mellitus in human immunodeficiency virus seropositive subject's co-
385	infected with mycobacterium tuberculosis. :8.
386	<ol> <li>Pimpin L, Drumright LN, Kruijshaar ME, Abubakar I, Rice B, Delpech V, et al.</li></ol>
387	Tuberculosis and HIV co-infection in European Union and European Economic
388	Area countries. European Respiratory Journal. 2011 Dec 1;38(6):1382–92.
389	<ol> <li>Bizune DJ, Kempker RR, Kagei M, Yamin A, Mohamed O, Holland DP, et al.</li></ol>
390	Treatment Complexities Among Patients with Tuberculosis in a High HIV
391	Prevalence Cohort in the United States. AIDS Res Hum Retroviruses. 2018 Dec
392	1;34(12):1050–7.
393	<ol> <li>Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association</li></ol>
394	between systemic inflammation and incident diabetes in HIV-infected patients
395	after initiation of antiretroviral therapy. Diabetes Care. 2010 Oct;33(10):2244–9.
396	<ol> <li>Kumar AMV, Singarajipura A, Naik B, Guddemane DK, Patel Y, Shastri S, et al.</li></ol>
397	HIV-infected presumptive tuberculosis patients without tuberculosis: How many
398	are eligible for antiretroviral therapy in Karnataka, India? Journal of
399	Epidemiology and Global Health. 2017 Mar 1;7(1):11–9.
400	<ol> <li>Pathmanathan I, Pasipamire M, Pals S, Dokubo EK, Preko P, Ao T, et al. High</li></ol>
401	uptake of antiretroviral therapy among HIV-positive TB patients receiving co-
402	located services in Swaziland. PLOS ONE. 2018 May 16;13(5):e0196831.
403	<ol> <li>Lee MP, Chan JWM, Ng KKP, Li PCK. Clinical manifestations of tuberculosis in</li></ol>
404	HIV□infected patients. Respirology. 2000 Dec;5(4):423–6.
405	22. WHO   Universal antiretroviral therapy (ART) for all HIV-infected TB patients
406	[Internet]. WHO. World Health Organization; [cited 2020 Jul 8]. Available from:
407	https://www.who.int/hiv/topics/tb/art_hivpatients/en/
408	23. WHO   Antiretroviral therapy for HIV infection in adults and adolescents [Internet].
409	WHO. World Health Organization; [cited 2021 Feb 7]. Available from:
410	https://www.who.int/hiv/pub/arv/adult2010/en/
411	24. da Silva Escada RO, Velasque L, Ribeiro SR, Cardoso SW, Marins LMS,
412	Grinsztejn E, et al. Mortality in patients with HIV-1 and tuberculosis co-infection
413	in Rio de Janeiro, Brazil - associated factors and causes of death. BMC Infect
414	Dis. 2017 May 30;17(1):373.
415	<ol> <li>A patient-level pooled analysis of treatment-shortening regimens for drug-</li></ol>
416	susceptible pulmonary tuberculosis   Nature Medicine [Internet]. [cited 2021 Jan
417	17]. Available from: https://www.nature.com/articles/s41591-018-0224-2
418	<ol> <li>Howell EM, Kigozi NG, Heunis JC. Community-based directly observed treatment</li></ol>
419	for TB patients to improve HIV services: a cross-sectional study in a South
420	African province. BMC Health Serv Res [Internet]. 2018 Apr 7 [cited 2020 Dec
421	2];18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889613/
422	<ol> <li>Cai E, Chua S, Tan M, Tambyah P. Tuberculosis care: enhancing directly</li></ol>
423	observed therapy in a peri-urban, low socioeconomic status neighbourhood.
424	smedj. 2019 Jul;60(7):334–6.

- 425 28. Getahun H, Gunneberg C, Granich R, Nunn P. HIV Infection—Associated
- 426 Tuberculosis: The Epidemiology and the Response. Clinical Infectious
- 427 Diseases. 2010 May 15;50(Supplement\_3):S201–7.


Gender, n (%) Male Female Transgender	285 (89.1)
Male Female Transgender	285 (89.1)
Transgender	
Transgender	33 (10.3)
-	2 (0.6)
Age at HIV diagnosis, median (IQR)	43.4 (37-55)
Age at TB diagnosis, median (IQR)	47.3 (41-57)
TB diagnosed by, n (%)	
Nucleic acid tests (eg. GeneXpert)	133 (41.4)
TB cultures	272 (84.7)
Clinical diagnosis	20 (6.2)
Previous TB history, n (%)	26 (8.1)
Presence of TB contact history, n (%)	27 (8.4)
Smoker, n (%)	144 (44.9)
Alcoholism, n (%)	76 (23.7)
History of cancer, n (%)	10 (3.1)
Diabetes mellitus, n (%)	40 (12.5)
End Stage Kidney Disease, n (%)	1 (0.3)
Hepatitis B, n (%)	31 (9.7)
Hepatitis C, n (%)	13 (4.0)
Receiving ART when diagnosed with TB, n (%)	74 (23.1)
Screened for latent TB upon HIV diagnosis, n (%) ¶	2 (0.6)
CD4 at TB diagnosis, mean $\pm$ s.d.	$125.0 \pm 153.9$ cells/mm <sup>3</sup>
CD4 >200cell/mL, n (%)	63 (19.6)
CD4 50-200 cells/mL, n (%)	120 (37.4)
CD4 <50 cells/mL, n (%)	124 (38.6)
Unknown, n (%)	13 (4.1)
HIV viral load at TB diagnosis, mean $\pm$ s.d.	935,142 ± 5,361,346 copies/r
Direct Observed Treatment, n (%)	267 (83)
Multi-drug resistant TB, n (%)	6 (1.9)
Time of starting ART, n (%)	
CD4≤50 cells/mm³	127 (39.7)
<2 weeks	18 (14.2)
2-8 weeks	27 (21.3)
>8 weeks	57 (44.9)
CD4>50 cells/mm <sup>3</sup>	179 (55.9)
<2 weeks	22 (12.3)
2-8 weeks	44 (24.6)
>8 weeks	62 (34.6)
Recurrence of TB, n (%)	12 (3.75)
Development of paradoxical IRIS, n (%)	50 (15.6)
Duration of TB treatment, mean $\pm$ s.d.	8.2 ± 3.5 months
Died, n (%)	32 (10)
TB-related	17 (5.3)
Non TB related	15 (4.7)
Lost to follow up, n (%)	12 (3.75)
Time between HIV diagnosis and death, median (IQR)	530 days (274-2413)

# 1 Table 1: Baseline characterisics of HIV-TB co-infected patients

4 TB, Tuberculosis.

5 ¶: Latent TB defined by positive testing by TST (tuberculin skin test) or IGRA


6 (interferon gamma release assay)



2



cells/mm<sup>3</sup> at TB diagnosis. (B) Patients with CD4>200 cells/mm<sup>3</sup> at TB diagnosis 4



# 3 Figure 2: Characteristics of pulmonary TB in HIV patients.

4 (A) Chest radiograph score of patients with CD4≤200 cells/mm<sup>3</sup> at TB diagnosis. (B)
5 Chest radiograph score of patients with CD4>200 cells/mm<sup>3</sup> at TB diagnosis. (C)
6 AFB smear quantity in patients with pulmonary TB, with CD4≤200 cells/mm<sup>3</sup> at TB
7 diagnosis. (D) AFB smear quantity in patients with pulmonary TB, with CD4>200
8 cells/mm<sup>3</sup> at TB diagnosis. (E) Association of AFB smear with chest radiograph in
9 patients with CD4≤200 cells/mm<sup>3</sup> at TB diagnosis. (F) Association of AFB smear with
10 chest radiograph in patients with CD4>200 cells/mm<sup>3</sup> at TB diagnosis.

1

